COL7A1 and recessive dystrophic epidermolysis bullosa: The development of topical gene editing therapies for RDEB can bypass the challenge of the large size of COL7A1 cDNA (∼9 kb) in gene replacement treatment and avoid long-term treatment with repeated application.